<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37338061</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1756-185X</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>International journal of rheumatic diseases</Title><ISOAbbreviation>Int J Rheum Dis</ISOAbbreviation></Journal><ArticleTitle>Cancer development in patients hospitalized with systemic lupus erythematosus: A population-level data linkage study.</ArticleTitle><Pagination><StartPage>1557</StartPage><EndPage>1570</EndPage><MedlinePgn>1557-1570</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/1756-185X.14784</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To explore the association between systemic lupus erythematosus (SLE) with the risk of cancer development and subsequent 5-year mortality in Western Australia (WA).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Population-level, data linkage study of SLE patients (n&#x2009;=&#x2009;2111) and general population comparators (n&#x2009;=&#x2009;21&#x2009;110) hospitalized between 1980 and 2014. SLE patients (identified by ICD-9-CM: 695.4, 710.0, and ICD-10-AM: L93.0, M32.0) were nearest matched (10:1) for age, sex, Aboriginality, and temporality. Follow up was from time zero (index SLE hospitalization) to cancer development, death or 31 December 2014. We assessed the risk of cancer development and subsequent 5-year mortality between SLE patients and comparators with univariate and multivariate-adjusted Cox proportional hazards regression models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">SLE patients had similar multivariate-adjusted risk (adjusted hazard ratio [aHR] 1.03, 95% confidence interval [CI] 0.93-1.15; p&#x2009;=&#x2009;.583) of cancer development. Cancer development risk was higher in SLE patients &lt;40&#x2009;years old (aHR 1.58, 95% CI 1.29-1.94; p&#x2009;&lt;&#x2009;.001), and from 1980 to 1999 (aHR 1.16, 95% CI 1.02-1.31; p&#x2009;&lt;&#x2009;.001). SLE patients had higher risk of developing cancer of the oropharynx (aHR 2.13, 95% CI 1.30-3.50), vulvo-vagina (aHR 3.22, 95% CI 1.34-7.75), skin (aHR 1.20, 95% CI 1.01-1.43), musculoskeletal tissues (aHR 2.26, 95% CI 1.16-4.40), and hematological tissues (aHR 1.78 95% CI 1.25-2.53), all p&#x2009;&lt;&#x2009;.05. After cancer development, SLE patients had increased risk of 5-year mortality (aHR 1.31, 95% CI 1.06-1.61); highest in patients &lt;50&#x2009;years old (aHR 2.03, 95% CI 1.03-4.00), and in those with reproductive system and skin cancers.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Hospitalized SLE patients had increased risk of multiple cancer sub-types. Following cancer development, SLE patients had increased risk of 5-year mortality. There is scope to improve cancer prevention and surveillance in SLE patients.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">Not applicable. This low-risk risk study used de-identified administrative linked health data.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. International Journal of Rheumatic Diseases published by Asia Pacific League of Associations for Rheumatology and John Wiley &amp; Sons Australia, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Raymond</LastName><ForeName>Warren David</ForeName><Initials>WD</Initials><Identifier Source="ORCID">0000-0002-2537-0070</Identifier><AffiliationInfo><Affiliation>Rheumatology Group, Medical School, University of Western Australia, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Preen</LastName><ForeName>David Brian</ForeName><Initials>DB</Initials><Identifier Source="ORCID">0000-0002-2982-2169</Identifier><AffiliationInfo><Affiliation>School of Population &amp; Global Health, University of Western Australia, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keen</LastName><ForeName>Helen Isobel</ForeName><Initials>HI</Initials><Identifier Source="ORCID">0000-0002-8469-2424</Identifier><AffiliationInfo><Affiliation>Rheumatology Group, Medical School, University of Western Australia, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology, Fiona Stanley Hospital, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inderjeeth</LastName><ForeName>Charles Anoopkumar</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0003-0535-963X</Identifier><AffiliationInfo><Affiliation>Rheumatology Group, Medical School, University of Western Australia, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nossent</LastName><ForeName>Johannes Cornelis</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0002-2833-7997</Identifier><AffiliationInfo><Affiliation>Rheumatology Group, Medical School, University of Western Australia, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Arthritis and Osteoporosis Foundation of Western Australia</Agency><Country/></Grant><Grant><Agency>Arthritis Australia</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Rheum Dis</MedlineTA><NlmUniqueID>101474930</NlmUniqueID><ISSNLinking>1756-1841</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014904" MajorTopicYN="N" Type="Geographic">Western Australia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">autoimmunity</Keyword><Keyword MajorTopicYN="N">cancer</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">lupus</Keyword><Keyword MajorTopicYN="N">survival</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>20</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>20</Day><Hour>7</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37338061</ArticleId><ArticleId IdType="doi">10.1111/1756-185X.14784</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Raymond WD, Lester S, Preen DB, et al. Hospitalisation for systemic lupus erythematosus associates with an increased risk of mortality in Australian patients from 1980 to 2014: a longitudinal, population-level, data linkage, cohort study. Lupus Sci Med. 2021;8:e000539. doi:10.1136/lupus-2021-000539</Citation></Reference><Reference><Citation>Song L, Wang Y, Zhang J, Song N, Xu X, Lu Y. The risks of cancer development in systemic lupus erythematosus (SLE) patients: a systematic review and meta-analysis. Arthritis Res Ther. 2018;20:270. doi:10.1186/s13075-018-1760-3</Citation></Reference><Reference><Citation>Zhang M, Wang Y, Wang Y, et al. Association between systemic lupus erythematosus and cancer morbidity and mortality: findings from cohort studies. Front Oncol. 2022;12. doi:10.3389/fonc.2022.860794</Citation></Reference><Reference><Citation>Wadstr&#xf6;m H, Arkema EV, Sj&#xf6;wall C, Askling J, Simard JF. Cervical neoplasia in systemic lupus erythematosus: a nationwide study. Rheumatology (Oxford). 2017;56:613-619. doi:10.1093/rheumatology/kew459</Citation></Reference><Reference><Citation>Tallbacka KR, Pettersson T, Pukkala E. Increased incidence of cancer in systemic lupus erythematosus: a Finnish cohort study with more than 25&#x2009;years of follow-up. Scand J Rheumatol. 2018;47:461-464. doi:10.1080/03009742.2017.1384054</Citation></Reference><Reference><Citation>Chen YJ, Chang YT, Wang CB, et al. Malignancy in systemic lupus erythematosus: a nationwide cohort study in Taiwan. Am J Med. 2010;123:1150.e1-6. doi:10.1016/j.amjmed.2010.08.006</Citation></Reference><Reference><Citation>Rezaieyazdi Z, Tabaei S, Ravanshad Y, et al. No association between the risk of breast cancer and systemic lupus erythematosus: evidence from a meta-analysis. Clin Rheumatol. 2018;37:1511-1519. doi:10.1007/s10067-017-3950-9</Citation></Reference><Reference><Citation>Cramb SM, Duncan EW, Aitken JF, Soyer HP, Mengersen KL, Baade PD. Geographical patterns in melanoma incidence across Australia: can thickness differentials reveal the key drivers? Ann Cancer Epidemiol. 2020;4:4.</Citation></Reference><Reference><Citation>Holman CD, Bass AJ, Rouse IL, et al. Population-based linkage of health records in Western Australia: development of a health services research linked database. Aust N Z J Public Health. 1999;23:453-459. doi:10.1111/j.1467-842x.1999.tb01297.x</Citation></Reference><Reference><Citation>World Health Organization &amp; International Conference for the Ninth Revision of the International Classification of Diseases (1975: Geneva). Manual of the international statistical classification of diseases, injuries, and causes of death: based on the recommendations of the ninth revision conference, 1975, and adopted by the Twenty-ninth World Health Assembly, 1975 revision. 1977. World Health Organization.</Citation></Reference><Reference><Citation>National Coding Centre. The Australian version of The international classification of diseases, 9th revision, clinical modification (ICD-9-CM). Sydney: National Coding Centre 1996.</Citation></Reference><Reference><Citation>National Centre for Classification in Health. The international statistical classification of diseases and related health problems, 10th revision, Australian modification (ICD-10-AM). Sydney: National Centre for Classification in Health, Faculty of Health Sciences, University of Sydney 1998.</Citation></Reference><Reference><Citation>Elsworthy AM, Claessen SM, Graham B, et al. Australian coding standards for ICD-10-AM and ACHI. 2013.</Citation></Reference><Reference><Citation>Ward MM. Estimating disease prevalence and incidence using administrative data: some ASSEMBLY required. J Rheumatol. 2013;40:1241-1243. doi:10.3899/jrheum.130675</Citation></Reference><Reference><Citation>Moores KG, Sathe NA. A systematic review of validated methods for identifying systemic lupus erythematosus (SLE) using administrative or claims data. Vaccine. 2013;31(Suppl 10):K62-K73. doi:10.1016/j.vaccine.2013.06.104</Citation></Reference><Reference><Citation>Arkema EV, J&#xf6;nsen A, R&#xf6;nnblom L, Svenungsson E, Sj&#xf6;wall C, Simard JF. Case definitions in Swedish register data to identify systemic lupus erythematosus. BMJ Open. 2016;6:e007769. doi:10.1136/bmjopen-2015-007769</Citation></Reference><Reference><Citation>Rosa GPD, Ortega MF, Teixeira A, et al. Causes and factors related to hospitalizations in patients with systemic lupus erythematosus: analysis of a 20-year period (1995-2015) from a single referral Centre in Catalonia. Lupus. 2019;28:1158-1166. doi:10.1177/0961203319861685</Citation></Reference><Reference><Citation>Bradshaw PJ, Alfonso HS, Finn J, Owen J, Thompson PL. Measuring the gap: accuracy of the Western Australian hospital morbidity data in the identification of adult urban aboriginal and Torres Strait islander people. Aust N Z J Public Health. 2009;33:276-279. doi:10.1111/j.1753-6405.2009.00388.x</Citation></Reference><Reference><Citation>Teng T-HK, Katzenellenbogen JM, Thompson SC, et al. Incidence of first heart failure hospitalisation and mortality in aboriginal and non-aboriginal patients in Western Australia, 2000-2009. Int J Cardiol. 2014;173:110-117. doi:10.1016/j.ijcard.2014.02.020</Citation></Reference><Reference><Citation>Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173:676-682. doi:10.1093/aje/kwq433</Citation></Reference><Reference><Citation>National Academies of Sciences E, and Medicine. Appendix C: Clarification of Cancer Groupings Used in Reporting Results, with Correspondence to National Institute for Occupational Safety and Health Cause-of-Death Codes and International Classification of Diseases Codes for Cancers. National Academies Press; 2016.</Citation></Reference><Reference><Citation>Dreyer L, Faurschou M, Mogensen M, et al. High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term followup study in a Danish cohort. Arthritis Rheum. 2011;63:3032-3037. doi:10.1002/art.30483</Citation></Reference><Reference><Citation>Bernatsky S, Ramsey-Goldman R, Labrecque J, et al. Cancer risk in systemic lupus: an updated international multi-Centre cohort study. J Autoimmun. 2013;42:130-135. doi:10.1016/j.jaut.2012.12.009</Citation></Reference><Reference><Citation>Ladouceur A, Tessier-Cloutier B, Clarke AE, et al. Cancer and systemic lupus erythematosus. Rheum Dis Clin North Am. 2020;46:533-550. doi:10.1016/j.rdc.2020.05.005</Citation></Reference><Reference><Citation>Busch RW, Kay SD, Voss A. Hospitalizations among Danish SLE patients: a prospective study on incidence, causes of admission and risk factors in a population-based cohort. Lupus. 2017;27(1):165-171. doi:10.1177/0961203317734919</Citation></Reference><Reference><Citation>Piga M, Casula L, Perra D, et al. Population-based analysis of hospitalizations in a West-European region revealed major changes in hospital utilization for patients with systemic lupus erythematosus over the period 2001-2012. Lupus. 2015;25(1):28-37. doi:10.1177/0961203315596597</Citation></Reference><Reference><Citation>Nossent J, Keen H, Preen DB, Inderjeeth CA. Temporal trends in hospitalisation for opportunistic infections in lupus patients in Western Australia. Lupus. 2022;31(12):1434-1440. doi:10.1177/09612033221115965</Citation></Reference><Reference><Citation>Schwartzman-Morris J, Putterman C. Gender differences in the pathogenesis and outcome of lupus and of lupus nephritis. Clin Develop Immunol. 2012;2012:1-9. doi:10.1155/2012/604892</Citation></Reference><Reference><Citation>Bossingham D. Systemic lupus erythematosus in the far north of Queensland. Lupus. 2003;12:327-331.</Citation></Reference><Reference><Citation>Segasothy M, Phillips PA. Systemic lupus erythematosus in aborigines and Caucasians in Central Australia: a comparative study. Lupus. 2001;10:439-444. doi:10.1191/096120301678646191</Citation></Reference><Reference><Citation>Grennan DM, Bossingham D. Systemic lupus erythematosus (SLE): different prevalences in different populations of Australian aboriginals. Aust N Z J Med. 1995;25:182-183. doi:10.1111/j.1445-5994.1995.tb02843.x</Citation></Reference><Reference><Citation>Taylor KP, Thompson SC. Closing the (service) gap: exploring partnerships between aboriginal and mainstream health services. Aust Health Rev. 2011;35:297-308. doi:10.1071/ah10936</Citation></Reference><Reference><Citation>Durey A, McEvoy S, Swift-Otero V, Taylor K, Katzenellenbogen J, Bessarab D. Improving healthcare for aboriginal Australians through effective engagement between community and health services. BMC Health Serv Res. 2016;16:224. doi:10.1186/s12913-016-1497-0</Citation></Reference><Reference><Citation>Markwick A, Ansari Z, Clinch D, McNeil J. Perceived racism may partially explain the gap in health between aboriginal and non-aboriginal Victorians: a cross-sectional population based study. SSM Popul Health. 2019;7:100310. doi:10.1016/j.ssmph.2018.10.010</Citation></Reference><Reference><Citation>Wilson M, Stearne A, Gray D, et al. The harmful use of alcohol amongst Indigenous Australians. Australian Indigenous Health Bulletin 10.</Citation></Reference><Reference><Citation>Vos T, Barker B, Begg S, Stanley L, Lopez AD. Burden of disease and injury in aboriginal and Torres Strait islander peoples: the indigenous health gap. Int J Epidemiol. 2009;38:470-477. doi:10.1093/ije/dyn240</Citation></Reference><Reference><Citation>Bond CJ, Singh D. More than a refresh required for closing the gap of indigenous health inequality. Med J Aust. 2020;212:198-199.e191. doi:10.5694/mja2.50498</Citation></Reference><Reference><Citation>Threlfall T, Thompson J. Cancer incidence and mortality in Western Australia, 2013. Statistical Series Number 101. Perth, Western Australia: Department of Health, 2015.</Citation></Reference><Reference><Citation>Singh AG, Crowson CS, Singh S, et al. Cancer risk in cutaneous lupus erythematosus: a population-based cohort study. Rheumatology (Oxford). 2016;55:2009-2013. doi:10.1093/rheumatology/kew291</Citation></Reference><Reference><Citation>Lu, M, Bernatsky, S, Ramsey-Goldman, R, et al. Non-lymphoma hematological malignancies in systemic lupus erythematosus. Oncology. 2013;85(4):235-240. doi:10.1159/000350165</Citation></Reference><Reference><Citation>Guo J, Ren Z, Li J, Li T, Liu S, Yu Z. The relationship between cancer and medication exposure in patients with systemic lupus erythematosus: a nested case-control study. Arthritis Res Ther. 2020;22:159. doi:10.1186/s13075-020-02228-6</Citation></Reference><Reference><Citation>Cobo-Ib&#xe1;&#xf1;ez T, Urruticoechea-Arana A, R&#xfa;a-Figueroa I, et al. Hormonal dependence and cancer in systemic lupus erythematosus. Arthritis Care Res. 2020;72:216-224. doi:10.1002/acr.24068</Citation></Reference><Reference><Citation>Dey D, Kenu E, Isenberg DA. Cancer complicating systemic lupus erythematosus-a dichotomy emerging from a nested case-control study. Lupus. 2013;22:919-927. doi:10.1177/0961203313497118</Citation></Reference><Reference><Citation>Park JK, Yang JA, Ahn EY, et al. Survival rates of cancer patients with and without rheumatic disease: a retrospective cohort analysis. BMC Cancer. 2016;16:381. doi:10.1186/s12885-016-2444-5</Citation></Reference><Reference><Citation>Morales-S&#xe1;nchez A, Fuentes-Panan&#xe1; EM. Human viruses and cancer. Viruses. 2014;6:4047-4079. doi:10.3390/v6104047</Citation></Reference><Reference><Citation>Johnson DK, Reynolds KM, Poole BD, et al. Contribution of viral infection to risk for cancer in systemic lupus erythematosus and multiple sclerosis. PLoS One. 2021;16:e0243150. doi:10.1371/journal.pone.0243150</Citation></Reference><Reference><Citation>H&#xf8;rding U, Junge J, Daugaard S, et al. Vulvar squamous cell carcinoma and papillomaviruses: indications for two different etiologies. Gynecol Oncol. 1994;52:241-246. doi:10.1006/gyno.1994.1039</Citation></Reference><Reference><Citation>Segal Y, Calabr&#xf2; M, Kanduc D, Shoenfeld Y. Human papilloma virus and lupus: the virus, the vaccine and the disease. Curr Opin Rheumatol. 2017;29:331-342. doi:10.1097/bor.0000000000000398</Citation></Reference><Reference><Citation>Sabatini ME, Chiocca S. Human papillomavirus as a driver of head and neck cancers. Br J Cancer. 2020;122:306-314. doi:10.1038/s41416-019-0602-7</Citation></Reference><Reference><Citation>Duong TH, Flowers LC. Vulvo-vaginal cancers: risks, evaluation, prevention and early detection. Obstet Gynecol Clin North Am. 2007;34:783-802. doi:10.1016/j.ogc.2007.10.003</Citation></Reference><Reference><Citation>Raymond WD, Hamdorf M, Furfaro M, Eilertsen GO, Nossent JC. Smoking associates with increased BAFF and decreased interferon-&#x3b3; levels in patients with systemic lupus erythematosus. Lupus Sci Med. 2021;8:e000537. doi:10.1136/lupus-2021-000537</Citation></Reference><Reference><Citation>Bilenchi R, Pisani C, Poggiali S, et al. Discoid lupus erythematosus of the vulva. Lupus. 2004;13:815-816. doi:10.1191/0961203304lu1062cr</Citation></Reference><Reference><Citation>Wendt M, Hammarstedt-Nordenvall L, Zupancic M, et al. Long-term survival and recurrence in oropharyngeal squamous cell carcinoma in relation to subsites, HPV, and p16-status. Cancers (Basel). 2021;13:2553.</Citation></Reference><Reference><Citation>Lai J, Elleray R, Nordin A, et al. Vulval cancer incidence, mortality and survival in England: age-related trends. BJOG. 2014;121:728-738; discussion 739. doi:10.1111/1471-0528.12459</Citation></Reference><Reference><Citation>Hong A, Lee CS, Jones D, et al. Rising prevalence of human papillomavirus-related oropharyngeal cancer in Australia over the last 2 decades. Head Neck. 2016;38:743-750. doi:10.1002/hed.23942</Citation></Reference><Reference><Citation>Patel C, Brotherton JM, Pillsbury A, et al. The impact of 10&#x2009;years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? Euro Surveill. 2018;23:1700737. doi:10.2807/1560-7917.ES.2018.23.41.1700737</Citation></Reference><Reference><Citation>Kim JH, Kim SO, Han DJ, et al. Post-transplant malignancy: a burdensome complication in renal allograft recipients in Korea. Clin Transplant. 2014;28:434-442. doi:10.1111/ctr.12328</Citation></Reference><Reference><Citation>Howley PM, Pfister HJ. Beta genus papillomaviruses and skin cancer. Virology. 2015;479-480:290-296. doi:10.1016/j.virol.2015.02.004</Citation></Reference><Reference><Citation>Shah AA, Igusa T, Goldman D, et al. Association of systemic lupus erythematosus autoantibody diversity with breast cancer protection. Arthritis Res Ther. 2021;23:64. doi:10.1186/s13075-021-02449-3</Citation></Reference><Reference><Citation>Bae EH, Lim SY, Han KD, et al. Systemic lupus erythematosus is a risk factor for cancer: a nationwide population-based study in Korea. Lupus. 2019;28:317-323. doi:10.1177/0961203319826672</Citation></Reference><Reference><Citation>Gadalla SM, Amr S, Langenberg P, et al. Breast cancer risk in elderly women with systemic autoimmune rheumatic diseases: a population-based case-control study. Br J Cancer. 2009;100:817-821. doi:10.1038/sj.bjc.6604906</Citation></Reference><Reference><Citation>Ruiz-Irastorza G, Ugarte A, Egurbide M, et al. Antimalarials may influence the risk of malignancy in systemic lupus erythematosus. Ann Rheum Dis. 2007;66:815-817.</Citation></Reference><Reference><Citation>Bernatsky S, Ramsey-Goldman R, Gordon C, et al. Prostate cancer in systemic lupus erythematosus. Int J Cancer. 2011;129:2966-2969. doi:10.1002/ijc.25956</Citation></Reference><Reference><Citation>Rai R, Chauhan SK, Singh VV, et al. Heat shock protein 27 and its regulatory molecules express differentially in SLE patients with distinct autoantibody profiles. Immunol Lett. 2015;164:25-32. doi:10.1016/j.imlet.2015.01.007</Citation></Reference><Reference><Citation>Li XB, Cao NW, Chu XJ, et al. Antimalarials may reduce cancer risk in patients with systemic lupus erythematosus: a systematic review and meta-analysis of prospective studies. Ann Med. 2021;53:1687-1695. doi:10.1080/07853890.2021.1981547</Citation></Reference><Reference><Citation>Liu Q, Luo XY, Jiang H, et al. Hydroxychloroquine facilitates autophagosome formation but not degradation to suppress the proliferation of cervical cancer SiHa cells. Oncol Lett. 2014;7:1057-1062. doi:10.3892/ol.2014.1879</Citation></Reference><Reference><Citation>Burningham Z, Hashibe M, Spector L, Schiffman JD. The epidemiology of sarcoma. Clin Sarcoma Res. 2012;2:14. doi:10.1186/2045-3329-2-14</Citation></Reference><Reference><Citation>Abdulqader SB, Almujaiwel N, Alshakweer W, Alzhrani G. High-grade spheno-orbital meningioma in patients with systemic lupus erythematosus: two case reports and literature review. Surg Neurol Int. 2020;11:367. doi:10.25259/SNI_583_2020</Citation></Reference><Reference><Citation>Westermann R, Zobbe K, Cordtz R, Haugaard JH, Dreyer L. Increased cancer risk in patients with cutaneous lupus erythematosus and systemic lupus erythematosus compared with the general population: a Danish nationwide cohort study. Lupus. 2021;30:752-761. doi:10.1177/0961203321990106</Citation></Reference><Reference><Citation>L&#xf6;fstr&#xf6;m B, Backlin C, Pettersson T, et al. Expression of APRIL in diffuse large B cell lymphomas from patients with systemic lupus erythematosus and rheumatoid arthritis. J Rheumatol. 2011;38:1891-1897. doi:10.3899/jrheum.101190</Citation></Reference><Reference><Citation>Gaipl US, Voll RE, Sheriff A, et al. Impaired clearance of dying cells in systemic lupus erythematosus. Autoimmun Rev. 2005;4:189-194. doi:10.1016/j.autrev.2004.10.007</Citation></Reference><Reference><Citation>Bernatsky S, Ramsey-Goldman R, Joseph L, et al. Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis. 2014;73:138-142. doi:10.1136/annrheumdis-2012-202099</Citation></Reference><Reference><Citation>Vallerskog T, Heimb&#xfc;rger M, Gunnarsson I, et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther. 2006;8:R167. doi:10.1186/ar2076</Citation></Reference><Reference><Citation>Bultink IEM, de Vries F, van Vollenhoven RF, Lalmohamed A. Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls. Rheumatology. 2020;60:207-216. doi:10.1093/rheumatology/keaa267</Citation></Reference><Reference><Citation>Brown JR, Skarin AT. Clinical mimics of lymphoma. Oncologist. 2004;9:406-416. doi:10.1634/theoncologist.9-4-406</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>